An improved high-performance liquid-chromatographic (HPLC) assay for the simultaneous determination of serotonin (5-HT) and 5-hydroxyindole-3-acetic acid (5-HIAA) in human urine is reported. Following the automated precolumn derivatization of urinary 5-HT and 5-HIAA with benzylamine, the derivatives are separated by isocratic elution on a reversed-phase C18 semi-microbore column, and are fluorometrically detected at an excitation wavelength of 345 nm and an emission wavelength of 480 nm. The detection limits of 5-HT and 5-HIAA are 7 and 5 nmol/l in urine (0.7 and 0.5 fmol/20-µl injection). The proposed automatic method permits a highly selective and sensitive determination of 5-HT and 5-HIAA in human urine without any sample purification.
Serotonin (5-hydroxytryptamine, 5-HT), one of the active metabolite of tryptophan, occurs mainly in the enterochromaffin cells of the intestine, the central nervous system and blood platelets, and is further metabolized primarily to 5-hydroxyindole-3-acetic acid (5-HIAA). 5-HT is implicated in several important physiological processes, including the homeostasis and regulation of the intestinal motility, and is also a neurotransmitter in the central nervous system where it plays a modulator role in behavioral control, sleep and feeding. 1 For clinical purposes, measuring 5-HT and 5-HIAA in biological fluids is indispensable for the diagnosis of pathological phenomena, such as carcinoid syndrome, 2 essential hypertension, 3 depression, 4 migraine 5 and Tourette syndrome. 6 Especially, urinalyses are useful because of their noninvasiveness.
Various high-performance liquid-chromatographic (HPLC) methods, including fluorometric 7, 8 and electrochemical detection, [9] [10] [11] have been described for the determination of 5-HT or 5-HIAA in urine. However, the majority of them lack sensitivity and specificity, or require complicated pretreatments, such as liquid-liquid extraction 8 and solid-phase extraction 9, 11 or column-switching 10 for the determination of these compounds in biological samples, since the crude sample contains many fluorescent and electrochemically active compounds that otherwise would interfere with the analysis. Moreover, the simultaneous determination of 5-HT and 5-HIAA is rarely achieved. For routine clinical analysis, in fact, a simple and reproducible method that enables a simultaneous determination of the active amine and the metabolite would be desirable.
Previously, a highly selective fluorometric method for the determination of 5-HIAA in human urine by postcolumn derivatization was reported. 12 The principle of the method was based upon the selective derivatization of 5-hydroxyindoles (5-HIs) with aromatic methylamines, such as benzylamine, in the presence of potassium hexacyanoferrate(III) in a weakly alkaline medium to form highly fluorescent oxazole derivatives, which have different maximum excitation (345 nm) and emission (480 nm) spectra from those of the native fluorescence of 5-HIs. 13 One of the great advantages of this novel method was its simplicity and that the method permitted direct sample injection without prior sample purification. However, in a previous study, 5-HT in urine could not be determined because the sensitivity of the postcolumn method was insufficient for the determination of 5-HT in urine, because the compound is normally present at an extremely low concentration. Furthermore, the separation of 5-HT from endogenous interfering substances could not be achieved in the previous study.
Here, we report on an improved automatic precolumn fluorescence derivatization HPLC method for the determination of 5-HIs 
Experimental

Reagents and solutions
Deionized and distilled water, purified with a Milli-Q Lab (Millipore, Milford, MA, USA) system, was used for all aqueous solutions. (Tokyo, Japan) and was used after purification by recrystallization with absolute ethanol. Potassium hexacyanoferrate(III) was purchased from Kishida Chemical (Osaka, Japan).
3-Cyclohexylaminopropanesulfonic acid (CAPS)
, N-Ac-5HT and 1-octanesulfonic acid sodium salt were obtained from Wako Pure Chemical Co. (Osaka, Japan). Other chemicals were of the highest purity available and were used as received.
Apparatus and chromatographic conditions
A schematic flow diagram of the automated chromatographic system is shown in Fig. 1 . The system consisted of a Hitachi (Tokyo, Japan) L-7100 liquid chromatograph pump, an automated derivatization and sampling apparatus composed of a GILSON 231 XL sampling injector (Villiers-le-Bel, France), a GILSON 402 syringe pump and a GILSON thermostatic sample rack with a 832 temperature regulator, a Hitachi L-7480 fluorescence detector and a Hitachi D-2500 integrator. An analytical column packed with Cadenza CD-C18 (150 × 2.0 mm i.d.; particle size, 5 µm; Imtakt Corporation, Kyoto, Japan) was employed. A mixture of acetonitrile and 15 mM sodium acetate buffer (pH 5.5) (34:66, v/v) containing 3 mM 1-octanesulfonic acid sodium salt was used as the mobile phase. The flow rate of the mobile phase was 0.15 ml/min, and the column effluent was monitored at an excitation wavelength of 345 nm and an emission wavelength of 480 nm.
Sample preparation and derivatization
Each urine sample (24 h) from healthy volunteers was collected in an amber-colored glass bottle containing 5 ml of 25% hydrochloric acid, and aliquots of 10 ml were stored at -20˚C prior to analysis. The urine was diluted 100 times with water and passed through a disposable filter (0.45 µm, 13 mm i.d., cellulose acetate). A 20 µl aliquot of the diluted samples was pipetted into polypropylene vials and set on a sample rack (SR in Fig. 1 ). The sample rack temperature was maintained at 10˚C. To the diluted samples were added 4 µl of 300 mM CAPS buffer (pH 12.0)-methanol (1:9, v/v), 12 µl of 500 mM benzylamine in 90% methanol and 4 µl of 70 mM potassium hexacyanoferrate(III) in 50% methanol, successively, and automatically. Twenty microliters of the reaction mixture were sucked into the injector valve and left standing at room temperature in the valve for 10 min. Finally, the reaction mixture was injected into the chromatograph. These derivatization processes, except for the dilution of urine samples, were progressed automatically by a 231 XL system. Figure 3 shows a typical chromatogram obtained with urine from a healthy volunteer. A good separation of the benzylamine derivatives of 5-HIAA and 5-HT from reagent-blank components was achieved. The peaks were attributed on the basis of the retention times compared with the standard, and also co-chromatography of the standard and a urine sample using 20 -40% acetonitrile as the mobile phase. When the analysis was performed without benzylamine and/or potassium hexacyanoferrate(III), peaks 2 and 3 in Fig. 3 were not observed in the chromatogram, even at a high detector sensitivity. These results suggest that peaks 2 and 3 are fluorescent derivatives of 5-HT and 5-HIAA, respectively. As described above, other biogenic 5-HIs, such as 5-HTP, N-Ac-5HT and 5-HTOL, also reacted with benzylamine to form the corresponding fluorescent derivatives under the present conditions. These compounds were eluted at retention times different from those of 5-HT and 5-HIAA, and did not affect the determination of 5-HT and 5-HIAA. Peaks 7 and 8 in the chromatogram (Fig. 3) were observed only when the reaction was performed with benzylamine and potassium hexacyanoferrate(III). Although discernment from N-Ac-5HT was difficult for peak 8, N-Ac-5HT showed a slightly, but certain different, retention time from peak 8 in Fig. 3 . Thus, it was suggested that the component of peak 8 was an endogenous reactive constituent other than N-Ac-5HT (the occurrence of N-Ac-5HT in urine has never been reported). Exact identities of peaks 7 and 8, however, were unknown. Furthermore, 5-HTOL, a minor metabolite of 5-HT, is known to excrete in urine as free and conjugated forms. However, the urinary levels of free 5-HTOL in healthy subjects are very low and normally 1% or less than that of 5-HIAA. 1, 14 Actually, 5-HTOL could not be successfully detected because a large unknown peak (peak 8 in Fig. 3 ) other than the 5-HIs appeared at retention times of 31 -33 min. Further, the peak for 5-HTP partially overlapped with peak 6′ (Fig. 3 ) due to unknown urinary substances. Because of these reasons, these compounds in urine could not be measured under the present chromatographic and sample preparation conditions.
Results and Discussion
Chromatographic conditions
Fluorescence derivatization
The derivatization conditions were optimized using standard solutions (n = 3) containing 5-HT and 5-HIAA instead of diluted urine samples. The effects of the reaction time and the sample rack temperature on the 5-HT and 5-HIAA peak heights were investigated. As shown in Fig. 4 , 5-HT and 5-HIAA, the peak heights reached a steady state after 10 min at all of the temperatures examined. Although a sample rack temperature of 4˚C or above gave maximal peak heights for 5-HT, 10˚C was required for 5-HIAA. For the long-term preservation of urine samples and reagent solutions (24 h), the condition of the sample rack temperature was set at less than 10˚C. Consequently, a reaction time of 10 min and a sample rack temperature of 10˚C were adopted for the proposed procedure. Figure 5 shows the effects of the adding order and the premixing combination of the reagents on the 5-HT and 5-HIAA peak heights. The highest peak heights for both 5-HT and 5-HIAA were observed when the reagents were separately added (CAPS buffer (A), benzylamine (B) and potassium hexacyanoferrate(III) (C), in that order) to the standard solution (S) (S -A -B -C in Fig. 5 ). As for 5-HIAA, single-or twostep derivatization procedures, i.e., when all the reagents [S -(A + B + C) in Fig. 5 ] or CAPS buffer and benzylamine [S -(A + B) -C in Fig. 5 ] were previously mixed, gave comparable 5-HIAA peak heights to a separate adding procedure. Table 1 gives the 24-h reproducibility of 5-HT and 5-HIAA. A separate adding procedure was selected for a highly sensitive and reproductive method of 5-HT and 5-HIAA (Fig. 5 and Table 1 ).
Other fluorescence derivatization conditions, the benzylamine and potassium hexacyanoferrate(III) concentrations and the pH of the CAPS buffer, were also optimized.
Calibration graph, precision, and detection limit
Linear relationships were observed between the 5-HT and 5-HIAA peak heights and the amounts of them applied to the system up to 500 pmol/injection. The calibration curve was carried out using the method of least squares. The linear correlation coefficients were 0.999 for 5-HT and 5-HIAA. The recoveries (mean ± SD, n = 5) of 5-HT and 5-HIAA added to the urine samples were 92.2 ± 3.2 and 88.5 ± 2.3%, respectively. The within-day precision (CV, n = 10) of 5-HT and 5-HIAA assays in normal samples were 1.5 and 1.2%, respectively. The lower limits of detection for 5-HT, 5-HIAA, 5-HTP, N-Ac-5HT and 5-HTOL were 7, 5, 60, 5 and 6 nmol/l in urine (0.7, 0.5, 6.0, 0.5 and 0.6 fmol/injection) at a signal-tonoise ratio of 3, respectively. The sensitivity of the presented method was 360 to 428-fold higher than that of the aforedescribed postcolumn method. 12 
Measurement of 5-HT and 5-HIAA in urine
The concentrations (mean ± S.D.) of 5-HT and 5-HIAA in urine from healthy volunteers (n = 7) measured by the presented method were 560 ± 133 nmol/24 h and 32.5 ± 8.2 µmol/24 h, respectively ( Table 2 ). The 5-HT and 5-HIAA concentrations were similar to those obtained by other workers. 11, 15, 16 
Conclusion
This study has provided an improved precolumn HPLC method for the determination of 5-HT and 5-HIAA in human urine. The method is sufficiently sensitive to measure trace amounts of 5-HT in human urine. The selectivity of the method permits the simultaneous determination of 5-HT and 5-HIAA without prior sample purification. The simplicity and reproducibility of the method are sufficient for routine analysis. 
